EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), progresses are being made to circumvent the mechanism of resistance to other TKIs such as gefitinib, erlotinib, afatinib, and dacotinib, due to secondary mutations of epidermal growth factor receptor (EGFR) kinase domain.